A high-quality franchise with exceptional cash conversion and four straight earnings beats is offset by failed price momentum and near-zero upside to analyst targets, making this a hold candidate rather than a fresh entry point until the technical picture and risk/reward geometry improve.
Thesis pillars
- High Quality Franchise Strong Cash Conversion→Stable
- Momentum Failed Minimum Gate→Stable
- Thin Upside Unfavorable Risk Reward→Stable
- +1 more pillar — see the Why tab for full reasoning
Merck & Company, Inc. (MRK) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $129.97 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.6% away).
Merck & Co. discovers, develops, and markets prescription medicines (including biologics), vaccines, and animal health products globally through its Pharmaceutical and Animal Health segments, generating $65.0 billion in total sales in 2025. Revenue flows primarily through drug... Read more
Sell if holding. Analyst target reached at $129.97 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.6% away). Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Score 5.2/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: conservative.
About Merck & Company, Inc.
About Merck & Company, Inc.
Keytruda/Keytruda Qlex generated $31.7 billion in 2025 — 49% of Merck's total company sales of $65.0 billion — and received FDA approval in September 2025 for a subcutaneous formulation (Keytruda Qlex) across most adult solid tumor indications. Gardasil/Gardasil 9 contributed $5.2 billion (down from $8.6 billion in 2024 due to significantly lower demand in China), while Winrevair reached $1.4 billion in its first full year of commercialization. Merck's Pharmaceutical segment totaled $58.1 billion and Animal Health $6.4 billion.
Merck earns revenue through its Pharmaceutical segment — selling primarily through drug wholesalers, retailers, hospitals, and managed health care providers — and its Animal Health segment, which sells to veterinarians, animal producers, and pet owners. Alliance revenues from Lynparza (in collaboration with AstraZeneca) contributed $1.5 billion and Lenvima (with Eisai) added $1.1 billion in 2025. The pricing environment is under pressure on multiple fronts: HHS selected Januvia for IRA government price-setting effective January 1, 2026, and Janumet/Janumet XR face government pricing effective January 1, 2027. Merck expects HHS to select Keytruda for IRA price-setting in 2027, with a resulting lower price effective January 1, 2029, after which U.S. Keytruda sales are expected to decline materially.
Show full overview
The patent cliff converges on several top products simultaneously. Bridion ($1.8 billion in 2025) loses U.S. market exclusivity in July 2026; Januvia and Janumet lose U.S. exclusivity in May 2026, with Merck expecting to lose nearly all domestic sales subsequently. Most critically, the primary Keytruda compound patent expires in December 2028, when biosimilar competition could begin, with European compound patent expiry in 2031 and potential data exclusivity challenges in Europe arising as early as July 2026.
See also: Healthcare · Drug Manufacturers - General
From Merck & Company, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-05Recent Developments — Merck & Company, Inc.
Latest news
- NEWS Merck (MRK) Q1 Earnings Report Preview: What To Look For - StockStory — StockStory neutral
- NEWS Why Merck (MRK) Shares Are Trading Lower Today - Yahoo Finance — Yahoo Finance negative
- NEWS Why Merck (MRK) Shares Are Trading Lower Today - StockStory — StockStory negative
- NEWS Merck & Co Inc Stock (MRK) Moved Down by 4.19% on Apr 21: A Full Analysis - TradingKey — TradingKey negative
- NEWS MRK Stock Soars As Keytruda Delivers Again In Q1, Winrevair Accelerates — CEO Signals Robust Phase 3 Readout Period Ahea — Stocktwits positive
Generated 2026-07-05T12:40:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductKeytruda49%10-K Item 1A: 'in 2025, sales of Keytruda represented 49% of the Company's total sales'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $129.97 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.6% away). Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Prior stop was $122.68. Score 5.2/10, moderate confidence.
Take-profit target: $127.68 (-1.5% upside). Prior stop was $122.68. Stop-loss: $122.68.
Analyst target reached - limited upside remaining; Near 52-week high (0.6% away); Leverage penalty (D/E 1.1): -0.5.
Merck & Company, Inc. trades at a P/E of 36.5 (forward 13.5). TrendMatrix value score: 4.9/10. Verdict: Sell.
36 analysts cover MRK with a consensus score of 3.9/5. Average price target: $131.
What does Merck & Company, Inc. do?Merck & Co. discovers, develops, and markets prescription medicines (including biologics), vaccines, and animal health...
Merck & Co. discovers, develops, and markets prescription medicines (including biologics), vaccines, and animal health products globally through its Pharmaceutical and Animal Health segments, generating $65.0 billion in total sales in 2025. Revenue flows primarily through drug wholesalers, retailers, hospitals, and managed care organizations, with Keytruda/Keytruda Qlex alone accounting for 49% of total sales.